FGEN - FibroGen, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Francisco,
United States
Type: Equity
FGEN price evolution
FGEN
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $113.69 | $120.91 | $152.59 | $188.55 |
| Short term investments | $121.9 | $130.43 | $183.13 | $167.4 |
| Net receivables | $12.55 | $31.69 | $25.6 | $17.65 |
| Inventory | $41.56 | $40.7 | $41.18 | $42.46 |
| Total current assets | $331.56 | $364.11 | $411.36 | $430.55 |
| Long term investments | $6.95 | $6.61 | $8.18 | $7.96 |
| Property, plant & equipment | $81.22 | $85.76 | $91.23 | $95.37 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $91.97 | $96.32 | $103.77 | $108 |
| Total investments | $128.85 | $137.03 | $191.31 | $175.35 |
| Total assets | $423.53 | $460.43 | $515.13 | $538.54 |
| Current liabilities | ||||
| Accounts payable | $17.96 | $19.22 | $12.8 | $71.28 |
| Deferred revenue | $170.29 | $161.53 | $172.91 | $179.58 |
| Short long term debt | $14.08 | $11.88 | $11.01 | $9.93 |
| Total current liabilities | $217.67 | $209.41 | $194.07 | $254.75 |
| Long term debt | $189.88 | $190.81 | $193.62 | $125.25 |
| Total noncurrent liabilities | $368.06 | $366.21 | $381.36 | $312.68 |
| Total debt | $203.96 | $202.69 | $204.63 | $135.18 |
| Total liabilities | $585.73 | $575.63 | $575.43 | $567.43 |
| Shareholders' equity | ||||
| Retained earnings | -$1841.92 | -$1785.69 | -$1722.07 | -$1634.39 |
| Other shareholder equity | -$6.88 | -$6.92 | -$6.25 | -$4.57 |
| Total shareholder equity | -$204.17 | -$157.17 | -$102.27 | -$68.82 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $113.69 | $135.82 | $171.22 | $678.39 |
| Short term investments | $121.9 | $266.31 | $233.97 | $8.14 |
| Net receivables | $12.55 | $16.3 | $17.4 | $41.88 |
| Inventory | $41.56 | $40.44 | $31.02 | $16.53 |
| Total current assets | $331.56 | $492.83 | $474.06 | $755.11 |
| Long term investments | $6.95 | $11.48 | $173.69 | $5.04 |
| Property, plant & equipment | $81.22 | $100.93 | $120.15 | $63.25 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $91.97 | $117.26 | $299.76 | $71.73 |
| Total investments | $128.85 | $277.79 | $407.66 | $13.19 |
| Total assets | $423.53 | $610.09 | $773.82 | $826.84 |
| Current liabilities | ||||
| Accounts payable | $17.96 | $30.76 | $26.1 | $24.79 |
| Deferred revenue | $170.29 | $198.46 | $202.66 | $145.02 |
| Short long term debt | $14.08 | $10.29 | $10.96 | $12.33 |
| Total current liabilities | $217.67 | $273.56 | $225.5 | $163.19 |
| Long term debt | $189.88 | $17.05 | $88.78 | $25.39 |
| Total noncurrent liabilities | $368.06 | $338 | $319.21 | $222.2 |
| Total debt | $203.96 | $139.22 | $99.73 | $37.72 |
| Total liabilities | $585.73 | $631.53 | $544.71 | $385.39 |
| Shareholders' equity | ||||
| Retained earnings | -$1841.92 | -$1557.69 | -$1264.03 | -$974.01 |
| Other shareholder equity | -$6.88 | -$5.72 | -$4.16 | -$4.5 |
| Total shareholder equity | -$204.17 | -$21.45 | $209.15 | $422.18 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $27.14 | $40.13 | $44.32 | $36.16 |
| Cost of revenue | $5.41 | $4.24 | $5.71 | $3.49 |
| Gross Profit | $21.73 | $35.89 | $38.61 | $32.67 |
| Operating activities | ||||
| Research & development | $51.7 | $61.19 | $95.48 | $74.49 |
| Selling, general & administrative | $24.22 | $25.57 | $31.18 | $34.27 |
| Total operating expenses | $75.93 | $99.37 | $126.66 | $108.76 |
| Operating income | -$54.2 | -$63.48 | -$88.05 | -$76.09 |
| Income from continuing operations | ||||
| EBIT | -$51.08 | -$58.51 | -$84.85 | -$74.26 |
| Income tax expense | $0.08 | $0.08 | -$0.23 | $0.07 |
| Interest expense | $5.07 | $5.02 | $3.07 | $2.37 |
| Net income | ||||
| Net income | -$56.23 | -$63.62 | -$87.68 | -$76.7 |
| Income (for common shares) | -$56.23 | -$63.62 | -$87.68 | -$76.7 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $147.75 | $140.73 | $235.31 | $176.32 |
| Cost of revenue | $18.85 | $20.28 | $12.87 | $8.87 |
| Gross Profit | $128.9 | $120.45 | $222.44 | $167.45 |
| Operating activities | ||||
| Research & development | $282.86 | $296.79 | $387.04 | $252.92 |
| Selling, general & administrative | $115.25 | $124.69 | $123.92 | $106.41 |
| Total operating expenses | $410.72 | $421.48 | $510.97 | $359.33 |
| Operating income | -$281.81 | -$301.02 | -$288.53 | -$191.88 |
| Income from continuing operations | ||||
| EBIT | -$268.7 | -$291.86 | -$288.6 | -$186.53 |
| Income tax expense | $0 | $0.36 | $0.35 | $0.36 |
| Interest expense | $15.53 | $1.44 | $1.07 | $2.4 |
| Net income | ||||
| Net income | -$284.23 | -$293.65 | -$290.02 | -$189.29 |
| Income (for common shares) | -$284.23 | -$293.65 | -$290.02 | -$189.29 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$56.23 | -$63.62 | -$87.68 | -$76.7 |
| Operating activities | ||||
| Depreciation | $1.88 | $2.38 | $2.71 | $2.96 |
| Business acquisitions & disposals | $0.66 | |||
| Stock-based compensation | $9.3 | $9.48 | $15.88 | $16.11 |
| Total cash flows from operations | -$18.32 | -$84.54 | -$110.57 | -$101.59 |
| Investing activities | ||||
| Capital expenditures | -$0.25 | -$0.68 | -$0.99 | -$0.59 |
| Investments | $10.49 | $54.9 | -$13.95 | $104.07 |
| Total cash flows from investing | $10.24 | $54.22 | -$14.29 | $103.48 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.04 | $20.44 | $31.66 | |
| Net borrowings | -$0.05 | -$0.02 | $71.1 | -$0.17 |
| Total cash flows from financing | -$0.25 | -$0.02 | $91.53 | $31.48 |
| Effect of exchange rate | $1.1 | -$1.33 | -$2.64 | -$0.53 |
| Change in cash and equivalents | -$7.23 | -$31.67 | -$35.97 | $32.85 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$284.23 | -$293.65 | -$290.02 | -$189.29 |
| Operating activities | ||||
| Depreciation | $9.93 | $10.6 | $14.81 | $22.05 |
| Business acquisitions & disposals | $0.66 | -$35 | -$25 | -$2.83 |
| Stock-based compensation | $50.77 | $65.6 | $71.16 | $72.72 |
| Total cash flows from operations | -$315.02 | -$145.93 | -$82.23 | $81.6 |
| Investing activities | ||||
| Capital expenditures | -$2.52 | -$3.73 | -$5.19 | -$3.99 |
| Investments | $155.52 | $127.85 | -$396.79 | $459.31 |
| Total cash flows from investing | $153.66 | $89.12 | -$426.97 | $452.49 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $52.14 | $4.18 | $12.7 | $37.83 |
| Net borrowings | $70.85 | $47.76 | -$5.89 | -$13.02 |
| Total cash flows from financing | $122.75 | $46.78 | -$0.56 | $13.34 |
| Effect of exchange rate | -$3.4 | -$5.48 | $2.6 | $4.7 |
| Change in cash and equivalents | -$42.01 | -$15.52 | -$507.17 | $552.13 |
News
|
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
Zacks via Yahoo Finance
21 Mar 2024
|
|
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
Zacks via Yahoo Finance
20 Mar 2024
|
|
3 Nightmare Nasdaq Stocks Not Worth Holding Another Day
InvestorPlace
20 Mar 2024
|
|
Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use
Zacks via Yahoo Finance
15 Mar 2024
|
|
AstraZeneca (AZN) to Acquire Amolyt Pharma for $1.05 Billion
Zacks via Yahoo Finance
14 Mar 2024
|
|
NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up
Zacks via Yahoo Finance
13 Mar 2024
|
|
Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why
Zacks via Yahoo Finance
13 Mar 2024
|
|
Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails
Zacks via Yahoo Finance
12 Mar 2024
|
|
Regeneron (REGN) Gets FDA Nod for Praluent Label Extension
Zacks via Yahoo Finance
12 Mar 2024
|
|
Over $1.7M Bet On Globalstar? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying -...
Benzinga
12 Mar 2024
|
Fundamentals
| Market cap | $105.68M |
|---|---|
| Enterprise value | $195.96M |
| Shares outstanding | 98.77M |
| Revenue | $147.75M |
|---|---|
| EBITDA | -$258.77M |
| EBIT | -$268.70M |
| Net Income | -$284.23M |
| Revenue Q/Q | -21.03% |
| Revenue Y/Y | 4.99% |
| P/E ratio | -0.37 |
|---|---|
| EV/Sales | 1.33 |
| EV/EBITDA | -0.76 |
| EV/EBIT | -0.73 |
| P/S ratio | 0.72 |
| P/B ratio | -0.54 |
| Book/Share | -2.00 |
| Cash/Share | 1.15 |
| EPS | -$2.88 |
|---|---|
| ROA | -58.68% |
| ROE | 213.54% |
| Debt/Equity | -2.87 |
|---|---|
| Net debt/EBITDA | -1.82 |
| Current ratio | 1.52 |
| Quick ratio | 1.33 |